openPR Logo
Press release

Drug Eluting Balloons Market Estimated to Expand at a Robust CAGR by 2025

04-10-2018 05:49 PM CET | Health & Medicine

Press release from: Transparency Market Research

Drug Eluting Balloons Market Estimated to Expand at a Robust CAGR

Drug eluting balloons, also known as drug-coated balloons, have been one of the new tools to overcome the problem of high restenosis rates for the use of stents in peripheral artery disease (PAD) or coronary artery diseases. Drug eluting balloons stop the formation of scar tissue by using antiproliferatives. Once stretched, drug eluting balloons elute the drug into the vessel well of arteries and stop plaque formation, leading to smooth blood flow.

However, drug eluting stents are not typically used in the legs due to a high rate of stent breakage which can cause restenosis. The drug, balloon stand, excipient to hold the drug on the balloon and regulate its release, and the balloon covering process are the major four components of a drug eluting balloon. Deliverability and durability of the drug into the vessel wall depends on the performance and guidance of the components of drug eluting balloons.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2321

Rise in prevalence of coronary artery disease and peripheral artery disease is one of the major factors propelling the market. Moreover, technological advancements in drug delivery system and the need for effective therapies that reduce the risk of complications such as stent restenosis in patients drives the global Drug Eluting Balloons Market. However, high surgery cost and certain limitations associated with drug eluting balloons are likely to hamper of the growth of the drug eluting balloons market in the next few years.

Based on product type, the global drug eluting balloons market can be segmented into peripheral drug eluting balloons and coronary drug eluting balloons. The coronary drug eluting balloons segment is likely to expand at a rapid pace during the forecast period. This is attributed to increase in incidence of coronary artery disease among the geriatric population. In terms of end-user, the drug eluting balloons market can be categorized into cath labs, hospitals, and ambulatory surgical centers. The hospitals segment is likely to expand at a rapid pace during the forecast period as the number of surgeries performed in hospitals is high as compared to cath lab and ambulatory surgical centers.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2321

In terms of region, the global drug eluting balloons market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Rise in the number of patients suffering from coronary arterial disease is the major reason driving the drug eluting balloons drug eluting balloons market in North America. Increase in demand for treatment and growing awareness about the introduction of new techniques and technological advances in drug delivery system for peripheral and coronary artery diseases are likely to propel the drug eluting balloons market in Europe. Rise in demand for effective therapies in reducing complications associated with drug eluting stents, increase in smoking, peripheral artery disease, diabetes, and obesity are the major factors that drive the drug eluting balloons market in Asia Pacific. Latin America and Middle East & Africa are expected to be moderate markets for drug eluting balloons.

Key players operating in the global drug eluting balloons market are Aachen Resonance, B. Braun Melsungen AG, Biotronik, Inc., C. R. Bard, Cook Medical, Inc., EuroCor, Boston Scientific, Inc., and Medtronic, among others.

View Report -

https://www.transparencymarketresearch.com/drug-eluting-balloons-market.htmlDrug eluting balloons, also known as drug-coated balloons, have been one of the new tools to overcome the problem of high restenosis rates for the use of stents in peripheral artery disease (PAD) or coronary artery diseases. Drug eluting balloons stop the formation of scar tissue by using antiproliferatives. Once stretched, drug eluting balloons elute the drug into the vessel well of arteries and stop plaque formation, leading to smooth blood flow.

However, drug eluting stents are not typically used in the legs due to a high rate of stent breakage which can cause restenosis. The drug, balloon stand, excipient to hold the drug on the balloon and regulate its release, and the balloon covering process are the major four components of a drug eluting balloon. Deliverability and durability of the drug into the vessel wall depends on the performance and guidance of the components of drug eluting balloons.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2321

Rise in prevalence of coronary artery disease and peripheral artery disease is one of the major factors propelling the market. Moreover, technological advancements in drug delivery system and the need for effective therapies that reduce the risk of complications such as stent restenosis in patients drives the global Drug Eluting Balloons Market. However, high surgery cost and certain limitations associated with drug eluting balloons are likely to hamper of the growth of the drug eluting balloons market in the next few years.

Based on product type, the global drug eluting balloons market can be segmented into peripheral drug eluting balloons and coronary drug eluting balloons. The coronary drug eluting balloons segment is likely to expand at a rapid pace during the forecast period. This is attributed to increase in incidence of coronary artery disease among the geriatric population. In terms of end-user, the drug eluting balloons market can be categorized into cath labs, hospitals, and ambulatory surgical centers. The hospitals segment is likely to expand at a rapid pace during the forecast period as the number of surgeries performed in hospitals is high as compared to cath lab and ambulatory surgical centers.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2321

In terms of region, the global drug eluting balloons market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Rise in the number of patients suffering from coronary arterial disease is the major reason driving the drug eluting balloons drug eluting balloons market in North America. Increase in demand for treatment and growing awareness about the introduction of new techniques and technological advances in drug delivery system for peripheral and coronary artery diseases are likely to propel the drug eluting balloons market in Europe. Rise in demand for effective therapies in reducing complications associated with drug eluting stents, increase in smoking, peripheral artery disease, diabetes, and obesity are the major factors that drive the drug eluting balloons market in Asia Pacific. Latin America and Middle East & Africa are expected to be moderate markets for drug eluting balloons.

Key players operating in the global drug eluting balloons market are Aachen Resonance, B. Braun Melsungen AG, Biotronik, Inc., C. R. Bard, Cook Medical, Inc., EuroCor, Boston Scientific, Inc., and Medtronic, among others.

View Report -

https://www.transparencymarketresearch.com/drug-eluting-balloons-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Drug Eluting Balloons Market Estimated to Expand at a Robust CAGR by 2025 here

News-ID: 1010436 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug